It is intended to provide MSCs for transplantation that have an improved post-transplantation cell survival rate and engraftment rate and are highly safe with fewer adverse reactions, and a method for conveniently producing MSCs for transplantation having a high cell survival rate and engraftment rate. As means therefor, the present invention provides a stem cell for transplantation comprising an MSC capable of overexpressing IL-10.

The present disclosure relates to heterogeneous cell compositions derived from canine or feline uterine tissue and methods of producing and use thereof. In some aspects, the heterogeneous cell compositions comprise a mixture of mesenchymal progenitor cells and epithelial progenitor cells. In some aspects, the heterogeneous cell compositions are used as an autologous or allogeneic treatment for the treatment of diseases such as chronic kidney disease, atopic dermatitis, immune mediated arthritis, hepatitis, liver disease, inflammatory bowel disease, osteoarthritis, intravertebral disc disease, keratoconjunctivitis sicca (dry eye), pancreatitis, fibrosis, sclerosis, amyloidosis, immune mediated polyarthritis or wounds in canines and felines.

A culture manufacturing method that includes: bringing adherent cells into contact with a dissolvable culture carrier that is larger than the size of the adherent cells and disposing the adherent cells on the surface of the dissolvable culture carrier, subjecting the adherent cells disposed on the surface of the dissolvable culture carrier to suspension culture in a culture medium, subjecting the dissolvable culture carrier to a modification treatment that modifies at least a portion of the surface in order to detach the adherent cells in the suspension culture from the surface of the dissolvable culture carrier, and, following the modification treatment, separating and harvesting the adherent cells from the modified dissolvable culture carrier that is larger than the size of the adherent cells on the basis of the size difference.

The present application relates to a plasma polymer thin film and a method for preparing the same, the plasma polymer thin film prepared using a first precursor material represented by the following Chemical Formula 1:

##STR00001##

(In Chemical Formula 1,

R.sub.1 to R.sub.9 are each independently H or a C.sub.1-C.sub.5 substituted or unsubstituted alkyl group, and when R.sub.1 to R.sub.9 are substituted, the substituent is an amino group, a hydroxyl group, a cyano group, a halogen group, a nitro group, or a methoxy group).

The present invention relates to a method for preparation of mesenchymal stem cells from human pluripotent stem cells and, more particularly, to a method for preparation of mesenchymal stem cells, wherein mesenchymal stem cells differentiated from embryoid bodies of a certain size in a xeno-free and serum-free environment are prepared, whereby the mesenchymal stem cells exhibit increased safety and maintain their own characteristics for a long period of time. A method for preparation of mesenchymal stem cells from human pluripotent stem cells according to the present invention employs a feeder cell-free, xeno-free, and serum-free culture environment to solve the problem of contamination with a foreign animal-derived material and allow the preparation of highly safe mesenchymal stem cells. In addition, the method utilizes spheroidal embryoid bodies to form mature embryoid bodies uniform in shape and size, thereby improving the differentiation efficiency to mesenchymal stem cells and exhibiting an exceptional effect of stably maintaining mesenchymal stem cell characteristics even after a long-term subculture, such as 20 or more passages, through which human pluripotent stem cell-derived mesenchymal stem cells can be prepared in a large amount. Therefore, the invention is advantageous for commercializing cell therapeutic agents superb in safety and efficiency.

The present disclosure relates to improved methods serum free stem cell culture, particularly 3D culture in bioreactors as well as cell culture medium and compositions for use in the same. Such methods may be particularly suitable for large scale cell manufacture.

Provided are methods of making and delivering vaccine compositions using an enucleated cell-based platform. Methods of clearing pathogenic infections in a subject using the enucleated cell-based platform is also provided. Such enucleated cell-based platform reduces the vaccine development timeline as compared with conventional biological vaccines, and improves vaccine efficacy.

Provided herein are CRIS-PR/Cas9 complexes and methods of using same.

The present disclosure relates to a method for producing extracellular vesicles from three-dimensionally cultured stem cells. The method of the present disclosure can produce stem cell-derived extracellular vesicles with a high yield through orbital shaking culture of stem cell aggregates in the presence of TGF-β and thus can be usefully used in an industrial-scale mass production process of exosomes that can be utilized as a pharmaceutical ingredient substituting for a cell therapeutic agent. Furthermore, the exosomes obtained by the method of the present disclosure have significantly improved immunoregulatory functions as compared to the exosomes produced by the existing method and, therefore, can be applied as a superior therapeutic composition for various inflammations or autoimmune diseases.

A mesenchymal stem cell culture product and a method for preparing the same are provided. The method for preparing the mesenchymal stem cell culture product includes the following steps. A predetermined quantity of mesenchymal stem cells is seeded in a flat culture device containing a first cell culture medium. When the mesenchymal stem cells proliferate to a target quantity, the first cell culture medium is replaced with a second cell culture medium, and the second cell culture medium is removed after incubation for 18 to 30 hours. A target cell culture medium is added and incubated for 48 to 72 hours. The target cell culture medium is collected repeatedly. The collected target cell culture medium is filtered and concentrated to obtain the mesenchymal stem cell culture product.